Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized multicenter comparison of CF, TP, and TN first-line chemotherapy for metastatic esophageal squamous cell carcinoma
ChiCTR1800015063Phase 3Recruiting
- Sponsor
- Nanyang Central Hospital
- Start
- Mar 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin, fluorouracil, paclitaxel and nedaplatin in Esophageal Squamous Cell Carcinoma (ESCC) (3 arms), sponsored by Nanyang Central Hospital. Primary endpoints: Progression-free survival and Chemotherapy toxicity reaction. Started Mar 2018; status: recruiting.
02
Drugs
cisplatinfluorouracilpaclitaxelnedaplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1800015063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015063.